Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Post by DigitalSpurson May 29, 2020 3:58pm

139 Views

Post# 31089668

AGN is VERY Promising right now

Bloomberg call on them earlier today
Drug is safe and has been around for a few decades
Tests show its promise and company has a 20X less market cap competitor in Bellus Health

Even if it's a quarter of the size, we are looking at a five fold increase from current price levels - I definitely see this running VERY quickly

IMO there will be a halt on Monday morning for some incredible news on the call scheduled

Over 40 cents next week is my guess!

Bullboard Posts

Canada Nickel unveils second of seven resources planned by mid-2025